Dose Insider / Glossary / Survodutide

SurvodutideWhat it is and what its trials showed

Updated November 20, 2026 路 3 min read 路 Lancet Diabetes Endocrinol 2024, SYNCHRONIZE-MASLD (Nat Med 2026)

Survodutide is an experimental weekly injection from Boehringer Ingelheim that activates two receptors, those for glucagon and for GLP-1, which makes it a dual agonist of a different kind from tirzepatide. In a 46-week phase 2 trial it lowered weight by up to 14.9%, against 2.8% on placebo.

14.9%4.8 mg, weight lost by week 46
Weight lost by week 46Phase 2 trial, % of starting weight4.8 mg14.9%3.6 mg13.2%2.4 mg12.5%0.6 mg6.2%Placebo2.8%Weight lost by week 46Phase 2 trial, % of starting weight4.8 mg14.9%3.6 mg13.2%2.4 mg12.5%0.6 mg6.2%Placebo2.8%

387 adults without diabetes; funded by Boehringer Ingelheim.

On this page

In a 2026 phase 3 trial in people with obesity and fatty liver disease, 84.2% saw liver fat fall by at least 30%.1,2 We found no label for it on DailyMed on November 20, 2026.3

What it is

The trial reports describe survodutide, coded BI 456906 during development, as a glucagon receptor and GLP-1 receptor dual agonist.1 Tirzepatide pairs GLP-1 with GIP; survodutide pairs it with glucagon, the pancreatic hormone that acts mainly on the liver. That pairing explains why one of its main phase 3 trials looked at liver fat as well as weight.2

The phase 2 trial

The phase 2 trial, published in 2024, enrolled 387 adults aged 18 to 75 with a body mass index of 27 or more and without diabetes, at 43 centers in 12 countries. They took survodutide 0.6, 2.4, 3.6 or 4.8 mg, or placebo, once a week for 46 weeks: 20 weeks of dose climbing and 26 weeks at the final dose.1

The authors concluded that all doses were tolerated and lowered weight in proportion to the dose. The trial was funded by Boehringer Ingelheim.1

SYNCHRONIZE-MASLD, the liver trial

This phase 3 trial, published in 2026, enrolled adults with obesity and metabolic dysfunction-associated steatotic liver disease, the condition formerly called fatty liver disease, at risk of progressing. They took survodutide 6.0 mg or placebo once a week for 48 weeks, 146 and 70 people respectively.2

The authors name the limits: 48 weeks is short, and participants came only from the United States and Spain. The most frequent side effects were in the stomach and gut, commonly during the dose climb, and mostly mild to moderate.2

Why two sets of numbers

The liver trial reports each result twice, and the gap matters. The first count includes only the time people stayed on the drug; the second counts everyone as assigned, whether or not they kept taking it. The second is the more cautious figure and closer to what happens when a medicine is used in practice. For weight, it gave 8.7% rather than 12.2%.2 The phase 2 trial, with 40% of people not completing it, shows why the difference can be large.1

What comes next

A cardiovascular outcomes trial, SYNCHRONIZE-CVOT, was designed to test survodutide's effect on heart events in people with obesity; its design was published in 2024.4 Until such results and a U.S. label exist, survodutide is a trial medicine, and any product sold online under its name is not one that FDA has reviewed for safety or quality.5 Our page on nausea on a GLP-1 applies to its side effects too.

Sources

  1. le Roux CW, Steen O, Lucas KJ, et al. Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial. Lancet Diabetes Endocrinol 2024;12:162-173. Funded by Boehringer Ingelheim. doi:10.1016/S2213-8587(23)00356-X
  2. Kaplan LM, Startseva E, le Roux CW, et al. Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease: SYNCHRONIZE-MASLD, a randomized, double-blind, placebo-controlled phase 3 trial. Nat Med 2026;32:2948-2958. doi:10.1038/s41591-026-04479-3
  3. DailyMed, U.S. National Library of Medicine. Search for "survodutide", no results; read November 20, 2026. dailymed.nlm.nih.gov
  4. Kosiborod MN, Platz E, Wharton S, et al. Survodutide for the treatment of obesity: rationale and design of the SYNCHRONIZE cardiovascular outcomes trial. JACC Heart Fail 2024. doi:10.1016/j.jchf.2024.09.004
  5. U.S. Food and Drug Administration. FDA's concerns with unapproved GLP-1 drugs used for weight loss. Content current as of October 1, 2026. fda.gov

Related analyses

Log any GLP-1 medicine you take and see your doses, weight and symptoms together.

Open Dose Insider